Open AccessConcise Review: Human Pluripotent Stem Cells to Produce Cell‐Based Cancer Immunotherapy
Author(s) -
Zhu Huang,
Lai YiShin,
Li Ye,
Blum Robert H.,
Kaufman Dan S.
Publication year - 2018
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.2754
Subject(s) - biology , induced pluripotent stem cell , cytotoxic t cell , cancer immunotherapy , immune system , immunotherapy , adoptive immunotherapy , adoptive cell transfer , immunology , cancer research , stem cell , lymphokine activated killer cell , microbiology and biotechnology , interleukin 21 , t cell , in vitro , embryonic stem cell , gene , genetics
Human pluripotent stem cells (PSCs) provide a promising resource to produce immune cells for adoptive cellular immunotherapy to better treat and potentially cure otherwise lethal cancers. Cytotoxic T cells and natural killer (NK) cells can now be routinely produced from human PSCs. These PSC‐derived lymphocytes have phenotype and function similar to primary lymphocytes isolated from peripheral blood. PSC‐derived T and NK cells have advantages compared with primary immune cells, as they can be precisely engineered to introduce improved anti‐tumor activity and produced in essentially unlimited numbers. S tem C ells 2018;36:134–145